Cenegermin Explained

Tradename:	Oxervate
Dailymedid:	Cenegermin
Pregnancy Au:	B3
Routes Of Administration:	Ophthalmic
Atc Prefix:	S01
Atc Suffix:	XA24
Legal Au:	S4
Legal Au Comment:	^[1] ^[2]
Legal Ca:	Rx-only
Legal Ca Comment:	/ Schedule D^[3]
Legal Us:	Rx-only
Legal Eu:	Rx-only
Cas Number:	1772578-74-1
Drugbank:	DB13926
Chemspiderid:	None
Unii:	B6E7K36KT8
Kegg:	D11028
Synonyms:	cenegermin-bkbj, Recombinant human nerve growth factor; rhNGF; human beta-nerve growth factor (beta-NGF)-(1-118) peptide (non-covalent dimer) produced in Escherichia coli
C:	583
H:	908
N:	166
O:	173
S:	8

Cenegermin, sold under the brand name Oxervate, also known as recombinant human nerve growth factor (rhNGF), is a recombinant form of human nerve growth factor (NGF). In July 2017, it was approved in the European Union as an eye drop formulation for the treatment of moderate or severe neurotrophic keratitis in adults.^{[4] [5]}

As a recombinant form of NGF, cenegermin is a peripherally selective agonist of the TrkA and LNGFR (p75^NTR) which must be administered parenterally.

The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.^[6]

History

It was developed by Anabasis Pharma, Dompé Farmaceutici, and Ospedale San Raffaele.^[7]

Research

In addition to neurotrophic keratitis, cenegermin is also under development for the treatment of dry eyes, retinitis pigmentosa, and glaucoma.

Further reading

• Sheha H, Tighe S, Hashem O, Hayashida Y . Update On Cenegermin Eye Drops In The Treatment Of Neurotrophic Keratitis . Clin Ophthalmol . 13 . 1973–1980 . October 2019 . 31631965 . 6789413 . 10.2147/OPTH.S185184 . free .

Notes and References

1. Web site: AusPAR: Cenegermin . Therapeutic Goods Administration (TGA) . 23 December 2019 . 26 August 2020 . 1 November 2021 . https://web.archive.org/web/20211101215946/https://www.tga.gov.au/auspar/auspar-cenegermin-rbe . dead .
2. Web site: Oxervate APMDS . Therapeutic Goods Administration (TGA) . 26 May 2022 . 10 March 2024.
3. Web site: Summary Basis of Decision (SBD) for Oxervate . . 23 October 2014 . 29 May 2022.
4. Web site: Oxervate EPAR . European Medicines Agency (EMA) . 17 September 2018 . 25 August 2020.
5. ((World Health Organization)) . 2017 . International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 77 . WHO Drug Information . 31 . 1 . 76 . 10665/330984 . free .
6. New Drug Therapy Approvals 2018 . U.S. Food and Drug Administration (FDA) . January 2019 . PDF . 16 September 2020.
7. Web site: Cenegermin - Dompe Farmaceutici - AdisInsight. 2020-06-05. adisinsight.springer.com.